The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal Syndrome: A Retrospective Cohort Study

Table 5

Summary of the results of multivariate analyses of 28-day mortality in HBV-derived HRS patients after PSM who received ALSS versus SMT treatment with risk stratification by number of organ failures or AKI degree.

Analysis	Treatment	Crude model		Model 1		Model 2
		HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
AKI stage 1	ALSS (SMT as reference)	1.03 (0.60-1.79)	0.908	1.04 (0.60-1.80)	0.892	0.76 (0.43-1.35)	0.352
AKI stage 2	ALSS (SMT as reference)	0.41 (0.13-1.35)	0.143	0.47 (0.14-1.64)	0.238	0.24 (0.03-1.90)	0.175
AKI stage 3	ALSS (SMT as reference)	0.37 (0.16-0.88)	0.024	0.34 (0.14-0.83)	0.018	0.29 (0.12-0.70)	0.006
Organ failure (≤ 1)	ALSS (SMT as reference)	0.72 (0.36-1.43)	0.345	0.72 (0.36-1.43)	0.344	0.68 (0.32-1.43)	0.307
Organ failure (≥ 2)	ALSS (SMT as reference)	0.41 (0.23-0.74)	0.003	0.42 (0.23-0.76)	0.004	0.52 (0.28-0.95)	0.033

Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, neutrophils, alanine aminotransferase (ALT), albumin, serum bilirubin, COSSH-ACLFs, and international normalized ratio (INR). AKI: acute kidney injury; SMT: standard medical treatment; ALSS: artificial liver support system.